2
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Neoplasms
18
Venous Thromboembolism
16
Venous Thrombosis
5
Pulmonary Embolism
4
Treatment of Venous Thromboembolism in Cancer Patients
3
Thrombosis
3
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Interventions
edoxaban
1
apixaban
1
Warfarin
1
Rivaroxaban
1
Heparin, Low-Molecular-Weight
1
Dalteparin
1
Dabigatran
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Embolism
×
Rivaroxaban
×
Clear all
NCT04618913
2026-05-26
VICTORIE
Pfizer
Active not recruiting
1 enrolled